Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
56 hedge funds and large institutions have $39.9M invested in Sio Gene Therapies Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 7 closing their positions.
99% more call options, than puts
Call options by funds: $787K | Put options by funds: $395K
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
4% more funds holding
Funds holding: 54 → 56 (+2)
31% less capital invested
Capital invested by funds: $57.7M → $39.9M (-$17.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.77M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$954K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$638K |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$516K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$251K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$8.11M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.27M |
| 3 |
TVWM
Tower View Wealth Management
Shorewood,
Wisconsin
|
-$1.6M |
| 4 |
Two Sigma Advisers
New York
|
-$464K |
| 5 |
Two Sigma Investments
New York
|
-$418K |
SIOX Hedge Fund Activity: Q3 2021 in Review
56 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q3 2021, worth a combined $39.9M — down 31% from $57.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SIOX positions and 7 closed out — a net gain of 3 holders — while 15 added to existing stakes and 12 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.77M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $8.11M sold.
- 56 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q3 2021, up from 54 in Q2 2021.
- Funds reported $39.9M of Sio Gene Therapies Inc. Common Stock stock for Q3 2021, down 31% quarter-over-quarter.
- 10 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q3 2021 and 7 closed out, a net change of +3 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q3 2021 was Renaissance Technologies, an estimated $1.77M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q3 2021 was Consonance Capital Management, an estimated $8.11M sold.
Based on aggregated 13F filings for Q3 2021.